Akeso, a biopharmaceutical firm based in China, released data on Wednesday indicating that its drug, ivonescimab, achieved superior results compared to AstraZeneca’s Imfinzi in a phase-three clinical trial. The study focused on patients with biliary tract cancer, a rare and aggressive form of cancer affecting the bile ducts. In the trial, patients were administered a combination of ivonescimab and chemotherapy, which the company reports showed improved outcomes over the standard treatment involving Imfinzi.

This development is notable for the broader Chinese biopharmaceutical sector, which is increasingly attempting to challenge established Western pharmaceutical giants. Ivonescimab has already attracted significant international attention, having been licensed by the U.S.-based company Summit Therapeutics in a deal valued at several billion dollars. The success of this trial is expected to bolster Akeso’s standing as it works to integrate its products into global medical markets. While the company has publicized these positive findings, the full peer-reviewed data from the phase-three trial has yet to be widely scrutinized by independent medical bodies. The trial results are being positioned as a breakthrough, though the long-term clinical implications and regulatory approval processes in markets outside of China remain the next hurdles for the company to clear.